E.I. du Pont de Nemours and Co.: The Conoco Split-off (A) Custom Case Solution & Analysis

Evidence Brief: DuPont-Conoco Divestiture

1. Financial Metrics

• IPO Proceeds: In October 1998, DuPont sold 30% of Conoco (191.5 million shares) at $16.00 per share, raising $4.4 billion.
• Debt Reduction: DuPont utilized $3.8 billion of the IPO proceeds to retire its own commercial paper and short-term debt.
• Valuation Gap: DuPont traded at a Price/Earnings (P/E) multiple significantly lower than pure-play life sciences competitors like Monsanto (approx. 20x vs. 35x).
• Remaining Interest: DuPont retains 435.4 million shares of Conoco Class B common stock, representing 70% of total equity.
• Tax Basis: To qualify as a tax-free reorganization under Section 355, DuPont must distribute at least 80% of its voting control in Conoco.

2. Operational Facts

• Strategic Pivot: DuPont is transitioning from a diversified chemical conglomerate to a science-based Life Sciences firm (Agriculture, Nutrition, Pharmaceuticals).
• Acquisition Context: Concurrent with the divestiture, DuPont is acquiring the remaining 80% of Pioneer Hi-Bred for $7.7 billion to bolster its agricultural seed position.
• Conoco Profile: An integrated energy company with significant upstream reserves and downstream refining/marketing assets. It contributed roughly 20-25% of DuPont total revenue but introduced significant earnings volatility due to commodity price fluctuations.
• Geography: Conoco operations span the U.S., North Sea, and Southeast Asia; DuPont is globally distributed with a primary focus on North American and European R&D.

3. Stakeholder Positions

• Chad Holliday (CEO, DuPont): Committed to the life sciences strategy. Views Conoco as a distraction to the market valuation of DuPont science core.
• Institutional Investors: Historically frustrated by the conglomerate discount. Many held DuPont for the chemical/science upside but were forced to accept oil exposure.
• Conoco Management: Seek independence to pursue capital investment in exploration without competing for internal funds against DuPont life science initiatives.
• The IRS: Requires a valid business purpose and continuity of interest for tax-free status; a split-off must meet specific exchange requirements.

4. Information Gaps

• Specific Exchange Premium: The case does not state the exact percentage premium required to entice shareholders to trade DuPont shares for Conoco shares.
• Oil Price Forecasts: Internal DuPont projections for crude oil prices during the 1999-2000 window are absent.
• Shareholder Overlap: The exact percentage of DuPont shareholders who specifically desire oil and gas exposure versus those who do not is not quantified.

Strategic Analysis: The Conoco Exit

1. Core Strategic Question

• How should DuPont divest its remaining 70% stake in Conoco to maximize the valuation of the remaining life sciences business while minimizing tax leakage and equity dilution?
• Can DuPont use the divestiture to proactively manage its own capital structure during the Pioneer Hi-Bred acquisition?

2. Structural Analysis

The conglomerate discount at DuPont is driven by Asset Misalignment. Investors seeking high-growth life sciences exposure are deterred by the capital-intensive, cyclical nature of Conoco. Under the Value Chain Lens, Conoco and DuPont share no meaningful operational overlaps; their integration was a 1981 defensive financial maneuver that now lacks industrial logic.

Applying a Capital Allocation Framework, the 70% stake in Conoco represents "trapped" capital. A spin-off merely hands the asset to shareholders, whereas a split-off allows DuPont to buy back its own shares using Conoco equity as the currency, effectively shrinking the DuPont equity base without cash outlay.

3. Strategic Options

4. Preliminary Recommendation

Execute a Split-off (Exchange Offer). This mechanism is superior because it simultaneously achieves two goals: the complete divestiture of a non-core asset and a massive share repurchase of DuPont stock. By retiring DuPont shares, the company increases the ownership stake of remaining shareholders in the high-growth life sciences core and improves Earnings Per Share (EPS) for the New DuPont.

Operations and Implementation Planner

1. Critical Path

• Step 1: Pricing Mechanism (Days 1-15): Establish the exchange ratio. A 10-15% premium over market price for Conoco is standard to incentivize the exchange.
• Step 2: SEC and IRS Filing (Days 16-45): Finalize the Prospectus-Offer to Exchange. Ensure compliance with Section 355 to maintain tax-free status.
• Step 3: Marketing and Roadshow (Days 46-75): Target institutional investors who specialize in energy (to take Conoco) and those who specialize in chemicals (to stay in DuPont).
• Step 4: Tender Period (Days 76-95): Open the offer for 20 business days. Monitor the subscription rate to ensure the 80% threshold is met.
• Step 5: Settlement (Day 100): Cancel the DuPont shares received and transfer Conoco Class B shares to participating investors.

2. Key Constraints

• Participation Risk: If fewer than the required number of DuPont shares are tendered, the offer fails. The premium must be calibrated to market volatility.
• Market Timing: A sudden drop in oil prices during the 20-day tender period would make Conoco shares less attractive, potentially collapsing the deal.
• Tax Integrity: Any deviation from the IRS-approved plan could trigger a multi-billion dollar tax bill for DuPont.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of undersubscription, DuPont should utilize an Upper Limit (Cap) on the exchange ratio to protect itself from extreme market swings, and a Dutch Auction element if necessary to find the clearing price. If the split-off is undersubscribed, the remaining Conoco shares should be distributed as a pro-rata spin-off (a clean-up spin) to ensure 100% divestiture by the deadline.

Executive Review and BLUF

1. BLUF

DuPont must execute the Conoco divestiture via a Split-off. This is the only path that eliminates the conglomerate discount while simultaneously retiring DuPont equity. By exchanging Conoco shares for DuPont shares, the company will reduce its shares outstanding by approximately 15-17%, providing an immediate boost to EPS for the remaining life sciences business. This move prepares the balance sheet for the Pioneer Hi-Bred integration and signals a definitive end to the diversified chemical era. APPROVED FOR LEADERSHIP REVIEW.

2. Dangerous Assumption

The analysis assumes that the market will re-rate DuPont to a life sciences multiple (30x+) immediately after the split. If the market continues to view DuPont as a cyclical chemical company despite the Conoco exit, the share retirement will have occurred at an overvalued price relative to the remaining core, destroying shareholder value.

3. Unaddressed Risks

• Execution Risk (High): The exchange offer requires active shareholder participation. A 15% premium may be insufficient if oil markets turn bearish during the 20-day window, leading to a failed offer.
• Regulatory Risk (Medium): The IRS Section 355 requirements are rigid. Any post-deal "active business" failure in the Conoco entity could retroactively disqualify the tax-free status.

4. Unconsidered Alternative

The team did not evaluate a Targeted Stock (Tracking Stock) for Conoco. While this would have highlighted the value of the energy assets, it would have failed to separate the balance sheets or provide the tax-free exit that the current market demands. However, it could have been a transitional step if market volatility made a full split-off impossible.

5. MECE Strategic Summary

• Financial Objective: Shrink equity base; eliminate oil-driven earnings volatility.
• Strategic Objective: Formalize the pivot to Life Sciences; enable focused capital allocation.
• Tax Objective: Execute under Section 355 to avoid 35% capital gains leakage.